Source:http://linkedlifedata.com/resource/pubmed/id/15384983
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2004-9-23
|
pubmed:abstractText |
Modified lipoproteins have been suggested to modulate endothelial expression of plasminogen activator inhibitor-1 (PAI-1). As oxidized high-density lipoprotein (Ox-HDL) has been found in atheromatous plaques and receptors for modified HDL are present on endothelial cells, we investigated the role of Ox-HDL3 on the expression of PAI-1. Ox-HDL3 but not native HDL3, increased PAI-1 mRNA expression in endothelial cells. Furthermore, PAI-1 antigen expression and activity increased in the supernatant of cells incubated with Ox-HDL3. The intracellular pathways involved in this effect were investigated. Ox-HDL3 activated both extracellular signal-regulated kinases (ERK) 1/2 and p38 mitogen-activated protein kinase (MAPK). Moreover, incubation with specific inhibitors of these kinases showed that p38MAPK was mainly involved in the Ox-HDL3-dependent PAI-1 induction. Transient transfection experiments suggested that none of the response elements in the proximal promoter (-804 to 17) were involved in Ox-HDL3-mediated PAI-1 expression. mRNA stability experiments showed that Ox-HDL3 increased the PAI-1 mRNA half-life. In summary, Ox-HDL3 induced PAI-1 mRNA expression and antigen release through a molecular mechanism involving MAPK activation and mRNA stabilization. Thus, oxidative modification converts HDL to a prothrombotic lipoprotein species.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Lipoproteins, HDL,
http://linkedlifedata.com/resource/pubmed/chemical/Lipoproteins, HDL3,
http://linkedlifedata.com/resource/pubmed/chemical/Plasminogen Activator Inhibitor 1,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/p38 Mitogen-Activated Protein...
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0007-1048
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright 2004 Blackwell Publishing Ltd
|
pubmed:issnType |
Print
|
pubmed:volume |
127
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
97-104
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:15384983-Cells, Cultured,
pubmed-meshheading:15384983-Dose-Response Relationship, Drug,
pubmed-meshheading:15384983-Endothelial Cells,
pubmed-meshheading:15384983-Endothelium, Vascular,
pubmed-meshheading:15384983-Gene Expression Regulation,
pubmed-meshheading:15384983-Humans,
pubmed-meshheading:15384983-Lipoproteins, HDL,
pubmed-meshheading:15384983-Lipoproteins, HDL3,
pubmed-meshheading:15384983-Oxidation-Reduction,
pubmed-meshheading:15384983-Plasminogen Activator Inhibitor 1,
pubmed-meshheading:15384983-Polymerase Chain Reaction,
pubmed-meshheading:15384983-RNA, Messenger,
pubmed-meshheading:15384983-p38 Mitogen-Activated Protein Kinases
|
pubmed:year |
2004
|
pubmed:articleTitle |
Oxidised-HDL3 induces the expression of PAI-1 in human endothelial cells. Role of p38MAPK activation and mRNA stabilization.
|
pubmed:affiliation |
Department of Pharmacological Sciences, University of Milan, Milan, Italy. danilo.norata@unimi.it
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|